INT82292

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1999
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 9
Disease Relevance 1.55
Pain Relevance 1.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (ABCC1) small molecule metabolic process (ABCC1) Golgi apparatus (ABCC1)
nucleolus (ABCC1) ATPase activity (ABCC1) plasma membrane (ABCC1)
Anatomy Link Frequency
T98G 1
d cells 1
ABCC1 (Homo sapiens)
Pain Link Frequency Relevance Heat
cINOD 22 99.62 Very High Very High Very High
vincristine 5 97.00 Very High Very High Very High
Bioavailability 3 88.64 High High
dexamethasone 1 70.16 Quite High
metalloproteinase 204 68.76 Quite High
Migraine 1 67.16 Quite High
Inflammation 85 50.00 Quite Low
cOX1 1 25.00 Low Low
COX2 1 25.00 Low Low
cytokine 155 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Herpes Simplex Virus 476 99.16 Very High Very High Very High
Rhabdomyolysis 4 88.56 High High
Muscle Disease 8 87.72 High High
Cancer 51 87.32 High High
Infection 219 81.28 Quite High
Death 12 79.52 Quite High
Lung Cancer 3 75.00 Quite High
Glioma 3 75.00 Quite High
Headache 1 67.16 Quite High
Sarcoma 158 50.00 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
MATERIALS AND METHODS: We chose sulindac as a candidate agent for further investigation as it has the most favourable efficacy and toxicity profile of the agents available for a potential specific MRP-1 inhibitor.
Negative_regulation (inhibitor) of MRP-1
1) Confidence 0.59 Published 2004 Journal Anticancer Res. Section Body Doc Link 15152944 Disease Relevance 0.09 Pain Relevance 0
CONCLUSION: Sulindac may be clinically useful as an inhibitor of the MRP-1 cancer resistance mechanism.


Negative_regulation (inhibitor) of MRP-1
2) Confidence 0.59 Published 2004 Journal Anticancer Res. Section Body Doc Link 15152944 Disease Relevance 0.06 Pain Relevance 0
In contrast, a multidrug resistance (MDR) phenotype due to expression of the multidrug resistance-associated protein (MRP) is most prominent in T98G cells and is amenable to modulation by indomethacin, suggesting that inhibition of MRP is at least in partly responsible for the potentiation of doxorubicin and vincristine cytotoxicity by NSAID.
Negative_regulation (inhibition) of MRP in T98G associated with vincristine and cinod
3) Confidence 0.49 Published 1999 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 10364464 Disease Relevance 0.20 Pain Relevance 0.99
We previously reported that a small number of NSAIDs could inhibit the activity of MRP-1.
Negative_regulation (inhibit) of MRP-1 associated with cinod
4) Confidence 0.43 Published 2004 Journal Anticancer Res. Section Abstract Doc Link 15152944 Disease Relevance 0.15 Pain Relevance 0.10
The transport parameters were not affected by the presence of MK-571, an inhibitor of multidrug resistance transporter P-glycoprotein (MRP).
Negative_regulation (inhibitor) of MRP
5) Confidence 0.42 Published 2003 Journal Planta Med. Section Abstract Doc Link 14735438 Disease Relevance 0.07 Pain Relevance 0.11
Cyclosporine (INN, ciclosporin) inhibits CYP3A4, P-glycoprotein (multidrug resistance protein 1), organic anion transporting polypeptide 1B1 (OATP1B1), and some other hepatic uptake transporters.
Negative_regulation (inhibits) of multidrug resistance protein 1
6) Confidence 0.41 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2672446 Disease Relevance 0.33 Pain Relevance 0
These results indicate that lovastatin, which can inhibit P-gp and MRP1, might be beneficial for reverting Sb resistance in VL [35].
Negative_regulation (inhibit) of MRP1
7) Confidence 0.09 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2771279 Disease Relevance 0.23 Pain Relevance 0
Levels of PGE2 in the supernatants of uninfected and KSHV infected HMVEC-d cells, and inhibitor treated or COX-2/lamin silenced and then uninfected or KSHV infected HMVEC-d cells, or TIVE and TIVE-LTC, COX inhibitor treated or untreated TIVE-LTC cells were measured by ELISA (Cayman Chemicals) according to the manufacturer's instructions [26].
Negative_regulation (inhibitor) of LTC in d cells associated with herpes simplex virus
8) Confidence 0.01 Published 2010 Journal PLoS Pathogens Section Body Doc Link PMC2820536 Disease Relevance 0.20 Pain Relevance 0.19
In MTT assays, we observed significant inhibition of TIVE-LTC cell metabolic activity with both drugs at all time points tested and the inhibition was marginally more with Indo for 72 h and 96 h (Figure 11C).
Negative_regulation (inhibition) of LTC
9) Confidence 0.01 Published 2010 Journal PLoS Pathogens Section Body Doc Link PMC2820536 Disease Relevance 0.22 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox